Processa Pharmaceuticals Inc logo

Processa Pharmaceuticals Inc(PCSA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.56
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PCSA

11/20/2026: PCSA (1-star) is currently NOT-A-BUY. Pass it for now.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for immunological and serious medical conditions. Following its strategic merger with Vidya Therapeutics and a substantial financing round, the company's investment story centers on advancing its lead oral BTK inhibitor candidate, VT-7208, through Phase 2 clinical trials. Key strengths include an expanded pipeline and strengthened cash reserves, while primary risks involve early-stage clinical trial uncertainties, pre-revenue status, and potential share dilution. The stock suits growth-oriented or speculative investors willing to accept high volatility, with clinical data readouts and regulatory updates serving as vital developments to monitor.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company offers high-growth optionality tied to clinical trial catalysts and pipeline expansion in immunology.
Momentum investorStrong fit while signal remains positiveShort-term price swings and high volume often occur around clinical data updates and corporate financing news.
Value investorWeak fitThe absence of commercial revenues and current lack of earnings make it unsuitable for traditional value metrics.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for drug development.
Low-risk investorWeak fitClinical-stage biotechnology investing entails high binary risk, regulatory uncertainty, and stock price volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap clinical-stage stocks experience sharp fluctuations based on trial data and market sentiment.
Valuation riskHighValuation relies heavily on future clinical potential rather than current financial earnings.
Competition risk (immunology and targeted therapies)Medium / highWell-capitalized competitors are advancing alternative treatments for similar indications.
Business qualityMediumThe enterprise is transitioning its clinical pipeline following recent strategic mergers.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess depends on executing complex clinical trials and securing regulatory clearances.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.37M USD
Price to earnings Ratio -
1Y Target Price 25
Price to earnings Ratio -
1Y Target Price 25
Volume (30-day avg) 44.2K shares
Beta 1.23
52 Weeks Range 1.04 - 8.88
Updated Date 11/20/2026
52 Weeks Range 1.04 - 8.88
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -66.21

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -70.93%
Avg. Invested days 8
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
PCSA receives a 2-star rating, supported by solid company fundamentals. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
PCSA has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and strong ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-14.5%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
PCSA's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
PCSA's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-14.5%, negative) and free-cash-flow growth (-1.2%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 135.8% and approximately 96.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 14.99% supports management-shareholder alignment.

Top 5 Institutional Investors

Connective Capital Management LLC 3.05%
Stonepine Capital Management Llc 1.97%
Geode Capital Management, LLC 0.79%
Citadel Advisors Llc 0.76%
XTX Topco Ltd 0.48%

Unit Economics (Per $1K Revenue)

★★★★★
PCSA generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
PCSA has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Therapeutics and LicensingFuture potential commercial sales, milestone payments, or licensing agreements derived from drug candidates such as VT-7208.The company currently generates no commercial revenue and operates entirely as a pre-revenue drug developer.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -807.93K
Price to Sales(TTM) 1320.06
Enterprise Value -807.93K
Price to Sales(TTM) 1320.06
Enterprise Value to Revenue 68.28
Enterprise Value to EBITDA -0.14
Shares Outstanding 2.80M
Shares Floating 2.70M
Shares Outstanding 2.80M
Shares Floating 2.70M
Percent Insiders 14.99
Percent Institutions 135.8

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.